These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 24560438

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence.
    Bisaga A, Sullivan MA, Cheng WY, Carpenter KM, Mariani JJ, Levin FR, Raby WN, Nunes EV.
    Drug Alcohol Depend; 2011 Dec 01; 119(1-2):e23-9. PubMed ID: 21715107
    [Abstract] [Full Text] [Related]

  • 3. The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone.
    Bisaga A, Sullivan MA, Glass A, Mishlen K, Pavlicova M, Haney M, Raby WN, Levin FR, Carpenter KM, Mariani JJ, Nunes EV.
    Drug Alcohol Depend; 2015 Sep 01; 154():38-45. PubMed ID: 26187456
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder.
    Sullivan MA, Bisaga A, Pavlicova M, Carpenter KM, Choi CJ, Mishlen K, Levin FR, Mariani JJ, Nunes EV.
    Am J Psychiatry; 2019 Feb 01; 176(2):129-137. PubMed ID: 30336703
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A week-long outpatient induction onto XR-naltrexone in patients with opioid use disorder.
    Sibai M, Mishlen K, Nunes EV, Levin FR, Mariani JJ, Bisaga A.
    Am J Drug Alcohol Abuse; 2020 May 03; 46(3):289-296. PubMed ID: 31860366
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Lorcaserin treatment for extended-release naltrexone induction and retention for opioid use disorder individuals: A pilot, placebo-controlled randomized trial.
    Levin FR, Mariani JJ, Pavlicova M, Choi CJ, Basaraba C, Mahony AL, Brooks DJ, Naqvi N, Bisaga A.
    Drug Alcohol Depend; 2021 Feb 01; 219():108482. PubMed ID: 33418204
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Influence of combined treatment with naltrexone and memantine on alcohol drinking behaviors: a phase II randomized crossover trial.
    Krishnan-Sarin S, O'Malley SS, Franco N, Cavallo DA, Tetrault JM, Shi J, Gueorguieva R, Pittman B, Krystal JH.
    Neuropsychopharmacology; 2020 Jan 01; 45(2):319-326. PubMed ID: 31590179
    [Abstract] [Full Text] [Related]

  • 14. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial.
    Lee JD, McDonald R, Grossman E, McNeely J, Laska E, Rotrosen J, Gourevitch MN.
    Addiction; 2015 Jun 01; 110(6):1008-14. PubMed ID: 25703440
    [Abstract] [Full Text] [Related]

  • 15. [Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomized trial].
    Krupitskiĭ EM, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Blokhina EA, Silverman BL.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012 Jun 01; 112(5 Pt 2):3-11. PubMed ID: 22951790
    [Abstract] [Full Text] [Related]

  • 16. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community.
    Di Paola A, Lincoln T, Skiest DJ, Desabrais M, Altice FL, Springer SA.
    Contemp Clin Trials; 2014 Nov 01; 39(2):256-68. PubMed ID: 25240704
    [Abstract] [Full Text] [Related]

  • 17. Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine.
    Sullivan M, Bisaga A, Pavlicova M, Choi CJ, Mishlen K, Carpenter KM, Levin FR, Dakwar E, Mariani JJ, Nunes EV.
    Am J Psychiatry; 2017 May 01; 174(5):459-467. PubMed ID: 28068780
    [Abstract] [Full Text] [Related]

  • 18. Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexone.
    Sullivan MA, Bisaga A, Glass A, Mishlen K, Pavlicova M, Carpenter KM, Mariani JJ, Levin FR, Nunes EV.
    Drug Alcohol Depend; 2015 Feb 01; 147():122-9. PubMed ID: 25555621
    [Abstract] [Full Text] [Related]

  • 19. Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial.
    DeFulio A, Everly JJ, Leoutsakos JM, Umbricht A, Fingerhood M, Bigelow GE, Silverman K.
    Drug Alcohol Depend; 2012 Jan 01; 120(1-3):48-54. PubMed ID: 21782353
    [Abstract] [Full Text] [Related]

  • 20. Extended-Release Injectable Naltrexone (XR-NTX) With Intensive Psychosocial Therapy for Amphetamine-Dependent Persons Seeking Treatment: A Placebo-Controlled Trial.
    Runarsdottir V, Hansdottir I, Tyrfingsson T, Einarsson M, Dugosh K, Royer-Malvestuto C, Pettinati H, Khalsa J, Woody GE.
    J Addict Med; 2017 Jan 01; 11(3):197-204. PubMed ID: 28379861
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.